2026 Q3 -tulosraportti
Vain PDF
27 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,96%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 14 | - | - | ||
| 99 | - | - | ||
| 18 | - | - | ||
| 61 | - | - | ||
| 14 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 733 | 49 733 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 733 | 49 733 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenHave earned well by shorting this with a leverage factor of 15. That's the good thing about stocks, you can earn both when they rise and fall. I hope my shorting hasn't contributed to pulling the price down so much that some small investors here have lost money.
·11 t sittenRemember that short sellers provide cheaper shares to others, so if one still believes in the case, they provide an opportunity to buy in cheaper (I am myself long in this stock and am at a loss). Short sellers take a very big risk, which we who are long do not have at all, so good luck to them.
·28.5.Roche LOI might be larger than the market understands: Roche is stopping the sale of their Cedex HiRes cell counter from mid-2026 and support only until March 2029. This means that 2,000+ GMP-approved pharma facilities globally are forced to switch instruments within 2 to 3 years, no matter what. The interesting thing is that the LOI with CHEMM does not seem to be random timing… Could it be that Roche is positioning XM30 as the preferred replacement for its own customers? That's a huge difference from having to fight against Beckman Coulter's established base from scratch Three possible outcomes as I see it: Scenario 1: No formal agreement -> limited effect, Beckman wins most… Scenario 2. Formal partnership agreement: CHEMM wins approx. 30% = 500 to 600 new XM instruments and up to DKK 110m in annual consumable revenue locked in behind FDA validation. Added value around DKK 100 to 150 per share Scenario 3: Exclusive agreement: 40 to 50% market share, DKK 200 to 300m in annual consumable revenue from the segment alone. Added value DKK 200 to 300+ per share At price 350, none of the scenarios are priced in. Roche and CHEMM have set 2026 as the timeframe for the initial work - the annual report on September 10th is the next natural milestone.
·3 päivää sittenIt's far from certain that this is a migration strategy from highRes to XM30, but it could be very profitable if Roche went out and recommended XM30, it would make it easier for GMP customers to switch to XM30. But but. There is also a more defensive explanation: Roche has identified XM30 as: * a promising technology * a growing player * relevant for Cedex Bio-customers and therefore only desires compatibility. In that scenario, the LOI becomes more of a "plug-in partnership" than a migration strategy. But if Roche at any point starts using formulations like: * "recommended workflow" * "migration path" * "successor solution" * "for existing Cedex HiRes customers" * "validated replacement" then the story suddenly becomes much bigger. :-)
·28.5.Børsen wrote, it was not about a new acquisition of a Danish company. It was about Roche buying the American biotech company Carmot Therapeutics, which was founded and led by the Danish researcher Stig K. Hansen. Therefore, the story in Denmark was referred to as “Roche buys Dane's company”, even though the company is not Danish.
·28.5.Børsen wrote the other day that Roche probably would buy a Danish company - do you know which one??????
·28.5.No, called the CEO the other day and he said such secret stock market news news does not concern an amateur investor like me 😳
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
Vain PDF
27 päivää sitten
7,00 DKK/osake
Viimeisin osinko
1,96%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenHave earned well by shorting this with a leverage factor of 15. That's the good thing about stocks, you can earn both when they rise and fall. I hope my shorting hasn't contributed to pulling the price down so much that some small investors here have lost money.·11 t sittenRemember that short sellers provide cheaper shares to others, so if one still believes in the case, they provide an opportunity to buy in cheaper (I am myself long in this stock and am at a loss). Short sellers take a very big risk, which we who are long do not have at all, so good luck to them.
- ·28.5.Roche LOI might be larger than the market understands: Roche is stopping the sale of their Cedex HiRes cell counter from mid-2026 and support only until March 2029. This means that 2,000+ GMP-approved pharma facilities globally are forced to switch instruments within 2 to 3 years, no matter what. The interesting thing is that the LOI with CHEMM does not seem to be random timing… Could it be that Roche is positioning XM30 as the preferred replacement for its own customers? That's a huge difference from having to fight against Beckman Coulter's established base from scratch Three possible outcomes as I see it: Scenario 1: No formal agreement -> limited effect, Beckman wins most… Scenario 2. Formal partnership agreement: CHEMM wins approx. 30% = 500 to 600 new XM instruments and up to DKK 110m in annual consumable revenue locked in behind FDA validation. Added value around DKK 100 to 150 per share Scenario 3: Exclusive agreement: 40 to 50% market share, DKK 200 to 300m in annual consumable revenue from the segment alone. Added value DKK 200 to 300+ per share At price 350, none of the scenarios are priced in. Roche and CHEMM have set 2026 as the timeframe for the initial work - the annual report on September 10th is the next natural milestone.·3 päivää sittenIt's far from certain that this is a migration strategy from highRes to XM30, but it could be very profitable if Roche went out and recommended XM30, it would make it easier for GMP customers to switch to XM30. But but. There is also a more defensive explanation: Roche has identified XM30 as: * a promising technology * a growing player * relevant for Cedex Bio-customers and therefore only desires compatibility. In that scenario, the LOI becomes more of a "plug-in partnership" than a migration strategy. But if Roche at any point starts using formulations like: * "recommended workflow" * "migration path" * "successor solution" * "for existing Cedex HiRes customers" * "validated replacement" then the story suddenly becomes much bigger. :-)
- ·28.5.Børsen wrote, it was not about a new acquisition of a Danish company. It was about Roche buying the American biotech company Carmot Therapeutics, which was founded and led by the Danish researcher Stig K. Hansen. Therefore, the story in Denmark was referred to as “Roche buys Dane's company”, even though the company is not Danish.
- ·28.5.Børsen wrote the other day that Roche probably would buy a Danish company - do you know which one??????·28.5.No, called the CEO the other day and he said such secret stock market news news does not concern an amateur investor like me 😳
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 14 | - | - | ||
| 99 | - | - | ||
| 18 | - | - | ||
| 61 | - | - | ||
| 14 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 733 | 49 733 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 733 | 49 733 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
2026 Q3 -tulosraportti
Vain PDF
27 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 10.9. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 6.5. | ||
2026 Q2 -tulosraportti 4.2. | ||
2026 Q1 -tulosraportti 7.11.2025 | ||
2025 Q4 -tulosraportti 12.9.2025 | ||
2025 Q3 -tulosraportti 7.5.2025 |
7,00 DKK/osake
Viimeisin osinko
1,96%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenHave earned well by shorting this with a leverage factor of 15. That's the good thing about stocks, you can earn both when they rise and fall. I hope my shorting hasn't contributed to pulling the price down so much that some small investors here have lost money.·11 t sittenRemember that short sellers provide cheaper shares to others, so if one still believes in the case, they provide an opportunity to buy in cheaper (I am myself long in this stock and am at a loss). Short sellers take a very big risk, which we who are long do not have at all, so good luck to them.
- ·28.5.Roche LOI might be larger than the market understands: Roche is stopping the sale of their Cedex HiRes cell counter from mid-2026 and support only until March 2029. This means that 2,000+ GMP-approved pharma facilities globally are forced to switch instruments within 2 to 3 years, no matter what. The interesting thing is that the LOI with CHEMM does not seem to be random timing… Could it be that Roche is positioning XM30 as the preferred replacement for its own customers? That's a huge difference from having to fight against Beckman Coulter's established base from scratch Three possible outcomes as I see it: Scenario 1: No formal agreement -> limited effect, Beckman wins most… Scenario 2. Formal partnership agreement: CHEMM wins approx. 30% = 500 to 600 new XM instruments and up to DKK 110m in annual consumable revenue locked in behind FDA validation. Added value around DKK 100 to 150 per share Scenario 3: Exclusive agreement: 40 to 50% market share, DKK 200 to 300m in annual consumable revenue from the segment alone. Added value DKK 200 to 300+ per share At price 350, none of the scenarios are priced in. Roche and CHEMM have set 2026 as the timeframe for the initial work - the annual report on September 10th is the next natural milestone.·3 päivää sittenIt's far from certain that this is a migration strategy from highRes to XM30, but it could be very profitable if Roche went out and recommended XM30, it would make it easier for GMP customers to switch to XM30. But but. There is also a more defensive explanation: Roche has identified XM30 as: * a promising technology * a growing player * relevant for Cedex Bio-customers and therefore only desires compatibility. In that scenario, the LOI becomes more of a "plug-in partnership" than a migration strategy. But if Roche at any point starts using formulations like: * "recommended workflow" * "migration path" * "successor solution" * "for existing Cedex HiRes customers" * "validated replacement" then the story suddenly becomes much bigger. :-)
- ·28.5.Børsen wrote, it was not about a new acquisition of a Danish company. It was about Roche buying the American biotech company Carmot Therapeutics, which was founded and led by the Danish researcher Stig K. Hansen. Therefore, the story in Denmark was referred to as “Roche buys Dane's company”, even though the company is not Danish.
- ·28.5.Børsen wrote the other day that Roche probably would buy a Danish company - do you know which one??????·28.5.No, called the CEO the other day and he said such secret stock market news news does not concern an amateur investor like me 😳
0
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 14 | - | - | ||
| 99 | - | - | ||
| 18 | - | - | ||
| 61 | - | - | ||
| 14 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 733 | 49 733 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 49 733 | 49 733 | 0 | 0 |